The European Society for Medical Oncology (ESMO) abstract release shows that AstraZeneca PLC and Daiichi Sankyo Co., Ltd. were right to temper expectations for the TROPION-Lung01 study of Dato-DXd (datopotamab deruxtecan) in non-small cell lung cancer, but the companies can take comfort in subgroup data that suggest its use case could be more convincing in the non-squamous population.
The TROP2-targeted antibody-drug conjugate is a key pipeline prospect for the firms to drive growth beyond 2025 and the less-than-effusive language in their topline release, plus mention of some grade 5 events (deaths), caused investors to take fright when the top-line data were released back in July
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?